CytoMed Therapeutics, a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, has entered into a Heads of Agreement (HoA) with CytoMed Therapeutics China, a company incorporated in Hong Kong, and a Memorandum of Understanding (MoU) with BioNex Solutions Inc.

The HOA forms a collaborative effort between CytoMed and CytoMed China to explore and investigate the safety, tolerability, potency, and efficacy of CytoMed's proprietary allogeneic gamma delta T cells for the treatment of various cancers (including solid tumours) in human subjects through an investigator-initiated trial (IIT) in the People's Republic of China. The IIT is to be initiated through an entity to be incorporated in Chongqing, a municipality directly under the Central Government.

Pursuant to the HoA, CytoMed will provide technical assistance in the planning and conduct of the clinical trial and will grant CytoMed China, a loan of up to an aggregate of S$1 million over three years.

In addition to this HoA, CytoMed has recently entered a MOU with BioNex Solutions Inc., a company incorporated/headquartered in Taiwan, Republic of China, to explore the potential application of CytoMed's unmodified allogeneic gamma delta T cells in patients who have no authorised therapy options for their relevant medical conditions.

Both the HoA and MoU were entered into just months after CytoMed announced that the chimeric antigen receptor gamma delta T cell (CAR-γδ T cell) technology, licensed exclusively to CytoMed from the Agency for Science, Technology and Research (A*STAR) of Singapore has been granted a patent by the China National Intellectual Property Administration (CNIPA).